Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2

[1]  Jianping Ding,et al.  Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus , 2022, Nature Communications.

[2]  D. Burton,et al.  A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, Science Translational Medicine.

[3]  D. Burton,et al.  A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, bioRxiv.

[4]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[5]  M. Beltramello,et al.  Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.

[6]  G. Pantaleo,et al.  A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma , 2021, Science Translational Medicine.

[7]  J. Taubenberger,et al.  Increasing threats from SARS-CoV-2 variants: Time to establish global surveillance , 2021, Science Translational Medicine.

[8]  A. Walls,et al.  Structural basis for broad coronavirus neutralization , 2021, Nature Structural & Molecular Biology.

[9]  B. Haynes,et al.  Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions , 2021, Cell Reports Medicine.

[10]  F. Grosveld,et al.  A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies , 2021, Nature Communications.

[11]  N. Sullivan,et al.  Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. , 2021, The New England journal of medicine.

[12]  P. Dormitzer,et al.  Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. , 2021, The New England journal of medicine.

[13]  E. Hodcroft,et al.  Public health actions to control new SARS-CoV-2 variants , 2021, Cell.

[14]  Lisa E. Gralinski,et al.  Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody , 2021, Science.

[15]  Lei Liu,et al.  Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry , 2021, Nature communications.

[16]  Peter B Rosenthal,et al.  Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.

[17]  S. Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[18]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[19]  Z. Rao,et al.  Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody , 2020, Science.

[20]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[21]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[22]  Jianqing Xu,et al.  Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies , 2020, Cellular & Molecular Immunology.

[23]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[24]  Y. Malik,et al.  Properties of Coronavirus and SARS-CoV-2. , 2020, The Malaysian journal of pathology.

[25]  Rongguang Zhang,et al.  Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody , 2020, Cellular & Molecular Immunology.

[26]  Zhènglì Shí,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[27]  Yuxian He,et al.  Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity , 2020, Journal of Virology.

[28]  James M. Hyman,et al.  New coronavirus outbreak: Framing questions for pandemic prevention , 2020, Science Translational Medicine.

[29]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[30]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[31]  Lu Lu,et al.  A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.

[32]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[33]  S. Hoffman,et al.  A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.

[34]  A. Walls,et al.  Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion , 2017, Proceedings of the National Academy of Sciences.

[35]  Jianping Ding,et al.  Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses , 2016, Nature Communications.

[36]  P. Zhou,et al.  Epitope-focused vaccine design against influenza A and B viruses. , 2016, Current opinion in immunology.

[37]  P. Collins,et al.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.

[38]  K. Yuen,et al.  Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.

[39]  Xavier Robert,et al.  Deciphering key features in protein structures with the new ENDscript server , 2014, Nucleic Acids Res..

[40]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[41]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[42]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[43]  Charles M. Rice,et al.  Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.

[44]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[45]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[46]  S. McNicholas,et al.  Presenting your structures: the CCP4mg molecular-graphics software , 2011, Acta crystallographica. Section D, Biological crystallography.

[47]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[48]  P. Talbot,et al.  Vacuolating encephalitis in mice infected by human coronavirus OC43 , 2003, Virology.

[49]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[50]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[51]  D. Burton,et al.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.

[52]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[53]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[54]  Vincent B. Chen,et al.  Acta Crystallographica Section D Biological , 2001 .

[55]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.